Cancer biomarkers for targeted therapy
Open Access
- 15 November 2019
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Biomarker Research
- Vol. 7 (1), 1-7
- https://doi.org/10.1186/s40364-019-0178-7
Abstract
Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer therapies. Antibody- based agents targeting the cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bispecific T cell engagers, and antibody-drug conjugates. Antibodies targeting CD19, CD20, CD22, CD30, CD33, CD38, CD79B and SLAMF7 are in clinical applications for hematological malignancies. CD123, CLL-1, B cell maturation antigen, and CD138 are targets for cancer immunotherapeutic agents, including the chimeric antigen receptor - engineered T cells. Immune checkpoint inhibitors (ICIs) against PD-1, PD-L1, and CTLA-4 have led to the revolution of cancer immunotherapy. More ICIs targeting IDO, LAG3, TIM-3, TIGIT, SIGLECs, VISTA and CD47 are being explored. Small molecule inhibitors (SMIs) against tyrosine kinase oncoproteins such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, EGFR, ALK, HER2, VEGFR, FGFR, MEK, and MET have fundamentally changed the landscape of cancer therapy. SMIs against BCL-2, IDHs, BRAF, PI3 kinase, mTOR, PARP, and CDKs have become the mainstay in the treatment of a variety of cancer types. To reduce and avoid off-tumor toxicities, cancer-specific TAAs such as CD33 are being manufactured through systems biology approach. Search for novel biomarkers and new designs as well as delivery methods of targeted agents are fueling the next wave of advances in cancer therapy.Keywords
This publication has 121 references indexed in Scilit:
- SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLBlood, 2013
- Ponatinib in Refractory Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2012
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical DevelopmentMolecular Cancer Therapeutics, 2012
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemiaInvestigational New Drugs, 2011
- Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivoInternational Journal of Oncology, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Mesothelin targeted cancer immunotherapyEuropean Journal Of Cancer, 2007
- AFP-specific CD4+ Helper T-cell Responses in Healthy Donors and HCC PatientsJournal of Immunotherapy, 2007
- Siglecs and their roles in the immune systemNature Reviews Immunology, 2007